The eQUANT™ System will support this hospital system's efforts to deliver timely results to providers, enabling appropriate management of sepsis patients and improving patient outcomes.
The eQUANT™ System is a game-changer in the global effort to combat antibiotic resistance and improve outcomes for sepsis patients. It delivers a standardized inoculum (0.5 McFarland equivalent) directly from positive blood cultures in approximately 70 minutes. By shortening the routine AST turnaround time by up to 24 hours, the eQUANT™ System enables faster, targeted therapy and boosts laboratory efficiency. Featuring a compact design, user-friendly interface, and cost-effective system, it integrates seamlessly into existing laboratory workflows and supports widespread adoption across a variety hospital settings.
Oren Knopfmacher, PhD, Co-Founder and CEO of Avails Medical said "I am so proud of the Avails team for this accomplishment and installing the first eQUANT™ Systems at such a prestigious institution. It truly is a testament to how novel and impactful the eQUANT™ System is in speeding up the time to actionable results for the sickest patients."
Avails Medical would also like to announce the appointment of Jason Kniebel as Vice President of Sales. Mr. Kniebel is a seasoned commercial executive with over 20 years of experience driving growth in the life sciences and diagnostics sectors. Most recently, he served as Vice President of Sales at T2 Biosystems, where he held leadership roles across sales, marketing, and commercial operations. "I am honored to join the incredible team at Avails Medical, which is committed to improving patient outcomes and fighting antimicrobial resistance through innovative, affordable, and rapid testing solutions," said Mr. Kniebel. "I look forward to leading the effort to drive sustainable business growth now and into the future."
About Avails Medical, Inc.
Avails Medical, Inc., a privately held company, was founded to address one of today's most pressing global health threats: antibiotic resistance. The company's all-electrical technology platform is designed to dramatically reduce the time required to generate reliable antibiotic susceptibility data, enabling faster and more accurate therapy decisions. Avails' proprietary electronic biosensor technology eliminates time-consuming manual culturing, improving the speed and accuracy of pathogen quantification and susceptibility testing directly from human specimens.
For more information please visit www.availsmedical.com.
